Tasca Therapeutics

Oncology

pharmaphorum caught up with Milenko Cicmil to talk about Tasca Therapeutics’ news at LSX: their first patient dosed for lead asset CP-383.

News

AstraZeneca prepares to move its oral GLP-1 elecoglipron into phase 3 for obesity and diabetes, after reporting encouraging phase 2b data at ADA.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.